Sobi reports 16 percent revenue growth in third quarter 2026

Swedish Orphan Biovitrum AB (Sobi) reported total revenue of SEK 9,124 million for the third quarter of 2026, marking a 16 percent increase at constant exchange rates compared to the same period last year. The financial results reflect sustained demand for the company's specialty pharmaceutical portfolio.

The Stockholm-based biopharmaceutical firm, which focuses on rare diseases and immunology, saw its revenue rise from SEK 7,776 million in the third quarter of 2025. Actual exchange rates pushed the growth figure to 17 percent.

Sobi’s performance is monitored by investors as a gauge of the rare disease drug market. The company continues to prioritize its clinical pipeline and international commercial expansion to maintain its market position in the therapeutic segments of hematology and immunology.